Toyobo Co., Ltd. · TSE:3101
Toyobo — H1 FY3/27 Earnings Presentation
26 slides from Toyobo's earnings presentation, Nov 9, 2026
Slide 1: Presentation to Investors
November 9, 2026 Presentation to Investors for the Second Quarter Ended September 30, 2026 TOYOBO CO., LTD.
Slide 2: Highlights
Highlights H1 FY 3/27 Results Although affected by the situation in the Middle East, Industrial film and Resin and chemical performed strongly, resulting in increases in net sales and operating profit. Net profit decreased due to impairment losses and other factors. Profit attributable to Net sales
Slide 3: Summary of Results: P&L
Summary of Results: P&L (¥ bn.) FY 3/26 FY 3/27 H1 YOY H1 H2 H1 Amount % Net sales 204.0 217.5 218.5 +14.4 +7.1% Gross profit 50.7 57.5 55.8 +5.1 +10.1% (Ratio to sales) 24.8% 26.4% 25.5% - - Operating profit 11.8 16.1 16.3 +4.5 +37.9% (Ratio to sales) 5.8% 7.4% 7.4% - - Non-operating income and exp
Slide 4: Non-operating Income and Expenses, Extraordinary Income and Losses
Non-operating Income and Expenses, Extraordinary Income and Losses Non-operating income and expenses: Extraordinary income and losses: breakdown (¥ bn.) breakdown (¥ bn.) FY 3/26 FY 3/27 FY 3/26 FY 3/27 YOY YOY H1 H1 H1 H1 Gain on sale of Dividend income 0.3 0.5 +0.3 - 1.3 +1.3 non-current assets Ot
Slide 5: Analysis in Changes in Operating Profit
Analysis in Changes in Operating Profit Volume Others 20.0 Prices +1.6 - 2.5 18.0 +6.0 16.0 Raw material 14.0 and fuel costs (¥bn.) 12.0 - 0.6 10.0 Films Depreciation Resin and chemical 16.3 8.0 ( +4.5 ) Industrial film increase 6.0 11.8 Resin and chemical increase Pharmaceuticals decrease 4.0 Shipm
Slide 6: Summary of Results: BS
Summary of Results: BS (B) (A) (¥ bn.) Mar. 31, 2025 Mar. 31, 2026 Sep. 30, 2026 (A)-(B) Total assets 617.8 627.7 609.4 - 18.2 Cash and deposits 28.6 31.1 26.8 - 4.3 Trade receivables 106.2 101.7 95.8 - 5.9 Inventories 119.0 128.1 130.9 +2.9 Property, plant and equipment 296.5 299.9 288.0 - 12.0 Net
Slide 7: Summary of Results: CF, etc.
Summary of Results: CF, etc. (¥ bn.) FY 3/26 FY 3/27 H1 YOY H1 H2 H1 Cash flows from operating activities 27.5 17.5 25.0 - 2.5 Cash flows from investing activities - 17.1 - 10.0 - 8.4 +8.7 Free cash flow 10.4 7.5 16.6 +6.2 Cash flows from financing activities - 13.0 - 3.5 - 20.6 - 7.6 Others 0.6 0.7
Slide 8: Summary of Results: Segment
Summary of Results: Segment (¥ bn.) Net sales Operating profit FY 3/26 FY 3/27 FY 3/26 FY 3/27 H1 YOY H1 H2* H1 H1 H2* H1 Films 86.5 88.6 97.4 8.6 8.0 13.2 +4.6 Life Science 16.5 18.0 18.3 0.1 -0.1 -1.6 - 1.7 Environmental and Functional Materials 50.7 59.4 55.6 3.1 6.6 5.2 +2.2 Fibers and Textiles
Slide 9: Films
Films (¥ bn.) FY 3/26 FY 3/27 H1 YOY Q1 Q2 H1 Q1 Q2 H1 Amount % Net sales 44.6 41.9 86.5 48.5 48.9 97.4 +10.9 +12.6% Operating profit 4.0 4.6 8.6 5.2 8.1 13.2 +4.6 +53.2% (OPM) 9.0% 11.0% 10.0% 10.7% 16.5% 13.6% - - EBITDA 6.5 7.1 13.6 8.2 11.2 19.4 +5.7 +42.1% Packaging film - Implemented price rev
Slide 10: Life Science
Life Science (¥ bn.) FY 3/26 FY 3/27 H1 YOY Q1 Q2 H1 Q1 Q2 H1 Amount % Net sales 8.0 8.5 16.5 9.1 9.2 18.3 +1.8 +10.9% Operating profit 0.2 - 0.0 0.1 - 0.5 - 1.1 - 1.6 - 1.7 - (OPM) 2.0% - 0.9% - - - - - EBITDA 1.1 1.0 2.1 0.7 0.4 1.1 - 1.0 - 45.3% Biotechnology - Sales of raw enzymes for diagnostic
Slide 11: Environmental and Functional Materials
Environmental and Functional Materials (mainly TOYOBO MC Corporation) (¥ bn.) FY 3/26 FY 3/27 H1 YOY Q1 Q2 H1 Q1 Q2 H1 Amount % Net sales 25.4 25.3 50.7 28.8 26.7 55.6 +4.8 +9.5% Operating profit 1.5 1.6 3.1 2.8 2.5 5.2 +2.2 +71.4% (OPM) 5.8% 6.3% 6.0% 9.6% 9.2% 9.4% - - EBITDA 2.6 2.7 5.3 4.1 3.8 7
Slide 12: Fibers and Textiles
Fibers and Textiles (¥ bn.) FY 3/26 FY 3/27 H1 YOY Q1 Q2 H1 Q1 Q2 H1 Amount % Net sales 19.6 20.3 39.9 18.8 18.7 37.5 - 2.4 - 6.1% Operating profit - 0.1 0.0 - 0.0 - 0.4 - 0.1 - 0.5 - 0.5 - (OPM) - 0.2% - - - - - - EBITDA 0.5 0.7 1.2 0.3 0.5 0.8 - 0.4 - 35.6% Textiles - Profitability declined due to
Slide 13: Forecasts for Business Environment in the FY 3/27
Forecasts for Business Environment in the FY 3/27 Segment Business Forecasts Packaging Same level year on year but expected to slow down slightly in the latter half. Films Continued strong demand for polarizer protective films for LCDs. Industrial Demand for MLCC for AI servers continues to grow. Bi
Slide 14: Forecasts for FY 3/27
Forecasts for FY 3/27 Industrial film and Resin and chemical remain strong, leading to an upward revision of full-year operating profit to ¥27.0 bn. Net profit is revised downward to ¥4.0 bn. due to impairment losses and the implementation of measures for challenged businesses. The annual dividend f
Slide 15: Analysis in Changes in Operating Profit
Analysis in Changes in Operating Profit Volume Others 35.0 Raw material Prices +3.0 - 5.9 and fuel costs +9.0 30.0 - 7.0 25.0 (¥ bn.) 20.0 Films Depreciation Resin and chemical 15.0 27.9 Industrial film increase 27.0 Resin and chemical increase 10.0 Pharmaceuticals decrease ( - 0.9) Shipments to the
Slide 16: Forecasts by Segment
Forecasts by Segment FY 3/26 Results FY 3/27 Forecasts Previous forecasts Net sales YOY (Aug. 2026) (¥ bn.) H1 H2* Full-year* H1 H2 Full-year Full-year Full-year Films 86.5 88.6 175.2 97.4 92.6 190.0 +14.8 185.0 Life Science 16.5 18.0 34.5 18.3 21.7 40.0 +5.5 39.0 Environmental and Functional Materi
Slide 17: Management Policy in FY 3/27
Management Policy in FY 3/27 Enhance earning power and asset efficiency to create the future 1. Thorough safety and disaster prevention, quality, and compliance (basic premise) 2. Realization of results from investment (CAPEX, investment in development) 3. Ensured pricing commensurate with value 4.
Slide 18: Progress of major growth investments
Realization of results from investment: Progress of major growth investments Industrial film - Demand remains strong due to the need for larger LCD screens. Production equipment for polarizer protective films - The launch of the modified equipment is progressing as planned. for LCDs ”COSMOSHINE SRF”
Slide 19: Pharmaceuticals, Textiles
Measures for challenged businesses: Pharmaceuticals, Textiles Contract manufacturing business of pharmaceuticals: Recording of Extraordinary Losses (Impairment Losses) - Impairment losses: ¥6.5 bn. - Substantial decrease in volume of orders received due to the emergence of competing products, result
Slide 20: Measures for challenged businesses: Airbag fabrics
Measures for challenged businesses: Airbag fabrics Conversion of airbag yarn manufacturer (Thailand) into a wholly owned subsidiary - Company name / Date of establishment: Toyobo Indorama Advanced Fibers Co., Ltd. (“TIAF”) / November 2020 - Date of share acquisition: October 30, 2026 Integrate hubs
Slide 21: Appendix
TOYOBO Appendix
Slide 22: Business Performance
Business Performance (¥ bn.) FY 3/26 FY 3/27 Net sales Q1 Q2 Q3* Q4* Full-year* Q1 Q2 Films 44.6 41.9 43.5 45.1 175.2 48.5 48.9 Life Science 8.0 8.5 8.3 9.7 34.5 9.1 9.2 Environmental and Functional Materials 25.4 25.3 27.2 32.2 110.1 28.8 26.7 Fibers and Textiles 19.6 20.3 19.7 20.9 80.5 18.8 18.7
Slide 23: Topics: Integrated Report
Topics: Integrated Report Toyobo Group’s Integrated Report “TOYOBO REPORT 2026” released Points of 2026 report - Provide details on the three measures outlined in the 2030 Medium-Term Management Plan: “Business portfolio reforms,” “Laying the groundwork for the future,” and “Foundation establishment
Slide 24: Topics: ESG
Topics: ESG Earns EcoVadis Silver Medal for sustainability performance - EcoVadis: Global sustainability ratings agency Assesses company’s initiatives across four themes: Environment, Labor and Human Rights, Ethics, and Sustainable Procurement - Earned an EcoVadis medal for eight consecutive years s
Slide 25: Please Note
Please Note The business performance forecasts and targets included in the business plans contained in this presentation are based on information known to the Company’s management as of the day of presentation. Please be aware that the content of the future forecasts may differ significantly from ac
Slide 26: TOYOBO CO., LTD. All rights reserved.
©️ TOYOBO CO., LTD. All rights reserved.